How should a patient with rheumatoid arthritis behave after achievement of remission?
The paper considers the very urgent problem of optimization of the management of rheumatoid arthritis (RA) patients who have achieved remission (or persistent low disease activity) during therapy using biologicals. It analyzes the results of BeSt, OPTIMA, HIT HARD, ACT-RAY, AVERT, PRESERVE, RETRO, P...
Main Author: | D. E. Karateev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2016-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/670 |
Similar Items
-
POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01) -
Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs)
by: Azamat Makhmudovich Satybaldyev
Published: (2013-03-01) -
USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01) -
How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity
by: D.E. Karateev
Published: (2014-05-01) -
Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
by: Irina Mikhailovna Marusenko
Published: (2013-12-01)